NCT03911102View on ClinicalTrials.gov

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

April 23, 2020

Study Completion Date

April 23, 2020

Conditions
Lateral Canthal Lines
Interventions
BIOLOGICAL

DaxibotulinumtoxinA for injection

Intramuscular injection

Trial Locations (4)

22209

Arlington, VA Site, Arlington

34239

Sarasota, FL Site, Sarasota

60143

Itasca, IL Site, Itasca

95816

Sacramento, CA Site, Sacramento

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT03911102 - Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines | Biotech Hunter | Biotech Hunter